• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by GeoVax Labs Inc.

    2/17/26 8:00:01 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    GeoVax Labs, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    373678705

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    373678705


    1Names of Reporting Persons

    L1 Capital Global Opportunities Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    547,715.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    547,715.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    547,715.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.79 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GeoVax Labs, Inc.
    (b)Address of issuer's principal executive offices:

    1955 Lake Park Drive, Suite 300, Smyrna, Georgia 30080
    Item 2. 
    (a)Name of person filing:

    L1 Capital Global Opportunities Master Fund, Ltd.
    (b)Address or principal business office or, if none, residence:

    161A Shedden Road, 1 Artillery Court, PO Box 10085 Grand Cayman, Cayman Islands KY1-1001
    (c)Citizenship:

    Cayman Islands
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    373678705
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    547,715 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on July 7, 2025 covering 1,475,000 shares of Common Stock purchased on July 2, 2025. The amounts in Row (5), (7) and (9) represent (i) 79,365 Warrants to purchase shares of Common Stock purchased on September 2025, (ii) 350,348 Warrants to purchase shares of Common Stock purchased on December 2025 and (iii) 118,000 Warrants to purchase shares of Common Stock purchased on July 2025. The percentage set forth on Row (11) of the cover page for the reporting person is based on 30,058,786 shares of Common Stock outstanding, based on the Issuer's Registration Statement on Form S-1 filed with the Securities and Exchange Commission on December 12, 2025. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.
    (b)Percent of class:

    1.79%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    547,715

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    547,715

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    L1 Capital Global Opportunities Master Fund, Ltd.
     
    Signature:/s/ David Feldman
    Name/Title:David Feldman, Director
    Date:02/17/2026
    Get the next $GOVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    4/11/25 1:23:33 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    4/10/25 4:01:15 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

    D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

    4/15/25 7:54:48 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

    Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

    4/15/25 7:54:17 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

    Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

    11/11/24 7:40:44 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 86 Day 2 September 25; Register to live stream

    MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – TodaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go b

    9/24/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Presenting on Emerging Growth Conference 86 Day 1 on September 24; Register to live stream

    MIAMI, Sept. 23, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 86th Emerging Growth Conference on September 24 & 25, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdaySeptember 24, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered,

    9/23/25 7:00:00 AM ET
    $ADVM
    $AIIO
    $BANL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Auto Manufacturing
    Industrials

    Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live stream

    MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered

    8/20/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    $GOVX
    SEC Filings

    View All

    GeoVax Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GeoVax Labs, Inc. (0000832489) (Filer)

    2/17/26 5:21:25 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by GeoVax Labs Inc.

    424B5 - GeoVax Labs, Inc. (0000832489) (Filer)

    2/17/26 10:33:35 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GeoVax Labs Inc.

    SCHEDULE 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    2/17/26 8:00:01 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by GeoVax Labs Inc.

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    10/20/25 9:11:05 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lemerond Nicole

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    6/6/25 9:51:40 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Leadership Updates

    Live Leadership Updates

    View All

    GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

    Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

    8/8/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

    Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

    1/8/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

    First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

    12/20/22 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by GeoVax Labs Inc.

    SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

    2/14/24 3:38:25 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

    2/10/21 3:16:30 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOVX
    Financials

    Live finance-specific insights

    View All

    GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

    Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

    11/12/24 4:00:00 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

    GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

    11/5/24 9:00:00 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

    Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

    8/6/24 4:00:00 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care